Sanara MedTech Inc.
HealthcareNASDAQ:SMTI · NASDAQ Capital Market
-$0.69 today
Vol 0.05M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-633.5%
avg -32.1%
ROIC
16.7%
avg -32.4%
ROA
-51.5%
avg -26.6%
Analysis
ROIC is currently the strongest return metric at 16.7% versus its period average of -32.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Seth Yon | President, Chief Executive Officer & Director | $2.14M | — | 51 | $109,546.00 | 1.20% |
Suresh V. Muppalla | President & Chief Executive Officer of THP | $872,006.00 | — | — | $2,973.00 | 0.03% |
Jacob A. Waldrop | Chief Operating Officer | $561,600.00 | — | 44 | $24,377.00 | 0.27% |
Elizabeth Taylor | Chief Financial Officer | $458,926.00 | — | 50 | $17,632.00 | 0.19% |
Ronald T. Nixon | Executive Chairman | $322,994.00 | — | 70 | $68,196.00 | 0.74% |
Bill Fitzgerald | Chief Compliance Officer | — | — | — | $0.00 | <0.01% |
Tricia Matteson | Vice President of Marketing | — | — | — | — | — |
Nina Bionda | Chief R&D Officer | — | — | — | — | — |
Tyler Palmer | Chief Corporate Development & Strategy Officer | — | — | — | — | — |
Ashley Mackey | Principal Accounting Officer | — | — | 40 | $4,967.00 | 0.05% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +42.2% | +35.7% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +42.2% over three years. Forward estimates point to Revenue at +35.7% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Viemed Healthcare, Inc.
NASDAQ:VMD
$400.62M
TruBridge, Inc.
NASDAQ:TBRG
$391.78M
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
Owens & Minor, Inc.
OMI
$207.07M
High Tide Inc.
NASDAQ:HITI
$203.04M
Stereotaxis, Inc.
AMEX:STXS
$179.84M
Exagen Inc.
NASDAQ:XGN
$112.83M
Who manages SMTI?
Sanara MedTech Inc. (SMTI) lists 10 active executives. The top listed executive is Elizabeth Taylor, Chief Financial Officer.
Are SMTI insiders buying or selling?
Recent insider activity shows net selling of $1.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.